Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 Mnf5R4VtdCCYaXHibYxqfHliQYPzZZk> NUn1bWZWOC1yLkWg{txO NXzkfnhLOjRiaB?= MmDp[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MkDiNlU3PjN5Nkm=
HepG2-HBV1.1 NGHvPZJCeG:ydH;zbZMhSXO|YYm= NGPSO3gxNTBwNTFOwG0> NEjkVJIzPCCq NFf1SpRqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 MWiyOVY3Ozd4OR?=
HepG2.2.15 M2DySWZ2dmO2aX;uJGF{e2G7 M{D0OFAvOSEQvF2= NVnRVGhqOjRiaB?= MnjJdJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;u MWSyOVY3Ozd4OR?=
HepG2-HBV1.1 NXrPXm92TnWwY4Tpc44hSXO|YYm= MYKwMlEh|ryP M3iyVlI1KGh? MVzwdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= NFrTWpUzPTZ4M{e2PS=>
HepG2-HBV1.1 NH7QRW1HfW6ldHnvckBCe3OjeR?= MXOwMlEh|ryP MUC0PEBp M3\adpBzd22xdHXzJINmdGxiZYjjdoV1cW:wIH;mJIhmeGG2aYTpd{BDKH[rcoXzJI52[2ynb3PhdJNq\HNiaX7zeIVi\CCxZjDo[ZBifGm2aYOgRkB3cXK3czDEZY5mKHCjcoTpZ4xmew>? M1zRdVI2PjZ|N{[5
HepG2-HBV1.1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonoNE4yKM7:TR?= NIP3ZmQyNTViZB?= MXvpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7 MXmyOVY3Ozd4OR?=
HepG2-HBV1.1 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\kNE4yKM7:TR?= M4ftRlEuPSCm NVe1R3NNcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=> MoWxNlU3PjN5Nkm=
HepG2-HBV1.1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKwMlEh|ryP MVKxNk04OiCq MV;pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JHMueGijc3W= M4X4dlI2PjZ|N{[5
HepG2-HBV1.1 M1PIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLPSWhxOC5zIN88US=> Ml;kNVIuPzJiaB?= M3ftcYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=> MljINlU3PjN5Nkm=
Raji M2CybWZ2dmO2aX;uJGF{e2G7 M1PhTVAvPcLizszN MW[3NkBp NGf2VVhi[m:uaYPo[ZMh[XW2b4DoZYd6yqB? NGDZU5kzPTR2NkO3Oy=>
SK-MEL-28  M3HVUGZ2dmO2aX;uJGF{e2G7 MkfNN|Ahdk1? NIO3cJM3KGh? MXHpcoR2[2W|IFey5qCUVSClZXzsMYN6[2ynIHHydoV{fA>? NXXYdlVOOjV|MUOwNVA>
H157 NILoPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnyPYd2UUN3ME2xMlA{KMLzIECuNFQhdWm3Ml2= MkTDNlUzPTd7MUG=
Jurkat M2n2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKxMVMhdk1? M4TQUFQ5yqCq M1zvfmROW09? M2j1b4Rm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> MkfwNlUyPTZzNE[=
CEM MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn0c2wyOS1|IH7N M1zISFQ5yqCq MkDZSG1UVw>? NYDISFBs\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? M2jzdFI2OTV4MUS2
P12 M{iwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLMd4oyNTNibl2= M3noVlQ5yqCq NVvYOGdTTE2VTx?= M{\rSIRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> Moj0NlUyPTZzNE[=
KB MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILOW5pKSzVyPUCuNFA1QSEEsTCwMlAxODFizszN NIG3W5EzPTB3OEWyOi=>
KBv200 (ABCB1) MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwM{S2NkDDuSByLkCwOlYh|ryP Mon4NlUxPTh3Mk[=
SUDHL6  MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrVNmR{OeLCid88US=> NHXmZlQ1QC95MjDo MVPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSC|aXfubYZq[2GwdHz5 MV6yOFk3OTZyNB?=
SUDHL6  NIDEWZFHfW6ldHnvckBCe3OjeR?= NHTKOZQy6oDLzszN NI\ST2Q4OiCq MnnabY5lfWOnczDzbYdvcW[rY3HueEBieG:ydH;0bYMhdW:{cHjvcI9ogSClaHHu[4V{KGOxdILld5Rm\CC5aYToJGJEVDFzQTDzbXJPSQ>? MmPtNlQ6PjF4MES=
HCT-116 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK1ZnhIUTVyPUWgcm0> MkHXNlQ6Ojd6NUe=
SKNBe2C M1jqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\yTWM2OD1|Mj64xtE1NjBibl2= M3LjU|I1QTJzOUKw
IGNR91 MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXpTWM2OD1{ND6zxtEyNjdibl2= NHPQVZkzPDl{MUmyNC=>
SKNAS M1nsZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXzZohKSzVyPUGuOeKyOC5{IH7N M4nvPFI1QTJzOUKw
LAN1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jNNGlEPTB;Mj6zxtExNjJibl2= M4HSSVI1QTJzOUKw
SHSY5Y MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofOTWM2OD16LkNCtVAvPiCwTR?= M1Hwb|I1QTJzOUKw
A549-WT NYj2PYZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTGOVFKSzVyPUG5MlQ{PyEEsTCwMlU6PCBibl2= MWOyOFg2QDh{Nx?=
A549-R MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DCWWlEPTB;MUKuNVc5KMLzIECuN|M{KCCwTR?= MnHjNlQ5PTh6Mke=
MCF-7-WT NF3IW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[xTJZKSzVyPUG3Mlc2OiEEsTCwMlIyQCBibl2= NVP0WXk{OjR6NUi4Nlc>
MCF-7-R MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjjNWxxUUN3ME21MlU{QSEEsTCwMlE1PCBibl2= NGrROGczPDh3OEiyOy=>
A549-R NYfue5pQS3m2b4TvfIlkcXS7IFHzd4F6 NEfHTIxKSzVyPUGyMlE4QCEEsTCwMlM{OyCwTR?= NEfRfoQzPDh3OEiyOy=>
MCF-7-R MnHJR5l1d3SxeHnjbZR6KEG|c3H5 MUHJR|UxRTVwNUO5JOKyKDBwMUS0JI5O MlLuNlQ5PTh6Mke=
SW620 M2fqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzrU4xmUUN3ME23MlgxKMLzIECuNFghdk1? MmnvNlQ4OjZ5M{m=
SW620/AD300 NFywXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO3fYdKSzVyPUmwPU43OCEEsTC4MlkyKG6P MWWyOFczPjd|OR?=
HEK293/pcDNA3.1 M{DEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwNEWgxtEhOC5{MDDuUS=> M2XqcVI1PzJ4N{O5
HEK293/ABCC1 MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XIfGlEPTB;MUmuNlkhyrFiMj6wPEBvVQ>? NGXXb5EzPDd{NkezPS=>
TCC M4fzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TuNlI1KGh? NH\RfWVKSzVyPUewJI5O NHTIRnIzPDdzNkm0OC=>
TCC MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTHUnVrPDhiaB?= MnjzTWM2OD13MDDuUS=> MYWyOFcyPjl2NB?=
HepG2/ADM Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OzU2lEPTB;Mj63PFY{yrFyLkKzO|Eh|ryP MVKyOFcxPDV3Nh?=
HepG2 M3f3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHPTWM2OD1yLkCxNVXDuTBwMECxO{DPxE1? M3zlRlI1PzB2NUW2
MCF-7/ADR Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHHTWM2OD12LkS4NlbDuTBwMkC3NEDPxE1? Ml:2NlQ4ODR3NU[=
MCF-7 NFG4V2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMEG1PeKyOC5yME[yJO69VQ>? M4e2W|I1PzB2NUW2
A-172  M2\j[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ryPFAvOcLizszN NE\yUGMzPC95MjDo NX7hb|E6cW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? MlTFNlQ2OzB{M{W=
U-251MG M4XlZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPSNE4yyqEQvF2= NYPjc41ROjRxN{KgbC=> MkjUbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> MnXRNlQ2OzB{M{W=
DLD-1 NFniUY5HfW6ldHnvckBCe3OjeR?= NInGTlIyODBibl2= NFrscmg1QCCq MVHwdo9ud3SnczDSWW5ZOyCmZX3leIh6dGG2aX;uxsA> NWDoeld7OjR2MEO0OVM>
CCD18Co NHKzW21HfW6ldHnvckBCe3OjeR?= MUOxNFAhdk1? NX75U25ZPDhiaB?= NYfqNY9CeHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi NGLKPXQzPDRyM{S1Ny=>
DLD-1 NUj0RlB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\2bY1lOC1zMECwJI5O NYTi[JJ4PDhiaB?= MVzpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M4DFdVI1PDB|NEWz
CCD18Co NHjiXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\uR4oxNTFyMECgcm0> NH7YW5E1QCCq MUHpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NGjqZpMzPDRyM{S1Ny=>
HepG2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rzWlI1KGh? MlSxTWM2OD13Mj615qCK|ryP MYiyOFM1OTZ6OB?=
HEK293/pcDNA3.1 M4i2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TnT2lEPTB;MD6wNFTDuTBwMECwN{DPxE1? Mn7JNlQzQDR5OEO=
HEK293/MRP1 NVvBR4dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonzTWM2OD1yLkC1OeKyOC5yMUKwJO69VQ>? Mn;SNlQzQDR5OEO=
Ramos NH7kPItCeG:ydH;zbZMhSXO|YYm= M{Plc|LjiIoQvF2= MnXKOFghcA>? MWHpcoR2[2W|IEO0MlYmyrFzLkmyKUBieG:ydH;zbZM> MXWyOFI2PjR7MR?=
NCI-H1299/pcDNA3 M{\FVGNmdGxiVnnhZoltcXS7IFHzd4F6 MYWwMVIxKG6P NEKwR5A6PiCq MU\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NXq2SlFvOjRzN{ewNVI>
H1299/ICAM-3 NF;ZZolE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NITiR28xNTJyIH7N M13ibVk3KGh? M3TtUolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MWmyOFE4PzBzMh?=
NCI-H1299/pcDNA3 NFL5RopHfW6ldHnvckBCe3OjeR?= M4\XWFEwPS9zMD:yNOKhdk1? MXu5OkBp NV3VXW11cW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? MXqyOFE4PzBzMh?=
H1299/ICAM-3 M{DlRmZ2dmO2aX;uJGF{e2G7 NULpNYNTOS93L{GwM|IxyqCwTR?= MWS5OkBp MYTpcoR2[2W|IHPs[YF3[WenIH;mJINie3Cjc3XzMVMtKDhuIEmsJIFv\CCSQWLQ M4[0RlI1OTd5MEGy
W1 NYTtRlR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMECzNkDPxE1? M{npfFI1OTRyMUe2
W1VR NEHEfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;3UHJKSzVyPUCuNFU3KM7:TR?= M{\GSVI1OTRyMUe2
K562 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr0TWM2OD1yLkCzNkDDuSByLkCwNUAh|ryP NEOyNFczPDF|NUmzOy=>
K562/ADR MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\xTWM2OD1|LkK2NUDDuSByLkSxNkDPxE1? NFvXSWozPDF|NUmzOy=>
K562 NXnFR3hLSXCxcITvd4l{KEG|c3H5 NIfXfGMxNjNizszN M13GOVI1KGh? Ml;hbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? NFnR[W4zPDF|NUmzOy=>
K562/ADR Mkn6RZBweHSxc3nzJGF{e2G7 NWn4PJhDOyEQvF2= M3jLSlI1KGh? MWLpcoR2[2W|IHHwc5B1d3Orcx?= MU[yOFE{PTl|Nx?=
A549 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuzUYM2UUN3ME2wMlExKMLzIECuNFMh|ryP MnrWNlM6PzFyN{W=
K562 MmS2R4VtdCCYaXHibYxqfHliQYPzZZk> MVizMlc26oDVNkFCpI5O M3nqW|czyqCqwrC= M1\s[4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M{XrVVI{QDd5MkKz
lucena NFLHSXBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWWzMlc26oDVNkFCpI5O M1TQ[|czyqCqwrC= M1PUPY5wKGWoZnXjeC=> M4m3cFI{QDd5MkKz
FEPS MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2fvNlMvPzYkgKO2NOKhdk1? Ml;0O|LDqGkEoB?= MlfIco8h\W[oZXP0 MofrNlM5Pzd{MkO=
A2780 NWXqT4p[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\3NGlEPTB;Mz61JI1O Mlz2NlM5Ojl{MEO=
ACHN MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkCxTWM2ODxyLkGgcW0> NGSxXZkzOzh{OUKwNy=>
U-937 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHhTWM2ODx|NDDuUS=> NEjDRnEzOzh{OUKwNy=>
Jurkat NUjpfpVxSXCxcITvd4l{KEG|c3H5 NGHBdpk2yqEQvHevcYzDqA>? MYCyOEBp NXv1dFJJcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= NVS2cHhxOjN6MUC0NFk>
Jurkat MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjyPXA2yqEQvHevcYzDqA>? MYeyOEBp NFHmWFNienKnc4SgTpVzc2G2IHPlcIx{KGmwIFeyM20heGijc3W= NHjwNYgzOzhzMESwPS=>
Hep-2 MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XXV2lEPTB;MD6wOOKyOC5yMTFOwG0> MonNNlM4QDB2MkS=
Hep-2/v NYDGNZZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn24TWM2OD1zLklCtVAvOjBizszN MVuyN|c5ODR{NB?=
SGC-7901 M13GeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nNWVAuOTBizsznM41t MoDSNlQwPDhxN{KgbC=> MoLCbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NIryVIgzOzd2M{W3Ni=>
SGC-7901/VCR M1vo[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL3Xo8xNTFyIN88[{9udA>? MY[yOE81QC95MjDo M3zYcIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NXXoVVE6OjN5NEO1O|I>
SGC-7901 M2PTfWFxd3C2b4Ppd{BCe3OjeR?= NXLuZ5J6cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= NFHvPG0zOzd2M{W3Ni=>
SGC-7901/VCR NEXoTolCeG:ydH;zbZMhSXO|YYm= NX\OPXBicW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= M3zjUlI{PzR|NUey
KB-3-1 NF3kbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwNk[gxtEhOC5zNkKg{txO NVXoSolFOjN4N{O0OFU>
KB-C2 M2mzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7CTWM2OD1{MEKuOVYhyrFiNEKuOFgyKM7:TR?= M4XiO|I{Pjd|NES1
KB-3-1 NH33OYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEOz[GhKSzVyPUGuNlYhyrFiMD6wNlch|ryP MlWxNlM3PzN2NEW=
KB-V1 NETmS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnzfXU4UUN3ME2yNFgvQDViwsGgNlAvPCEQvF2= NVHGcotSOjN4N{O0OFU>
HEK293/pcDNA3.1 NIDLfVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP0WFI5UUN3ME2yOE4yKMLzIECuNlA1KM7:TR?= NX;RTop{OjN4N{O0OFU>
HEK293/ABCB1 NUDIbm04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHxbZJKSzVyPUO1NVIvQCEEsTCzO|gvOzlzIN88US=> NVfBOFN5OjN4N{O0OFU>
A549/EGFP  NWLiWlhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjQXlJ4OC5yMT2xNFAxKM7:TR?= MmDUTWM2OD16Nj63JOKyKDJ7LkGg{txO NVfjWVN6OjN4M{SyPFI>
A549/Slug M3zGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXaNE4xOS1zMECwJO69VQ>? NGXCSoNKSzVyPUmuO{DDuSB|LkGg{txO NYqyWIxDOjN4M{SyPFI>
JFCR39  M2jiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nGOlEhyrWP MlrLNlQhcA>? NHrIdGVFVVOR M1H6eI1iemunZHz5JIlv[3KnYYPld{B1cGViboXtZoVzKG:oIFeyM20heGijc3WgZ4VtdHN? M4fGOVI{PTl6Mke2
A549 NXG1Um1nTnWwY4Tpc44hSXO|YYm= MVyxNFAhdk1? M4HQTFE3KGh? NGL1XHVFVVOR MnuzcIVi\HNidH:gZUBtd3O|IH;mJI1q[3KxdIXieYxmew>? M17rcVI{PTl6Mke2
SGC7901 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W4dWlEPTB;MT6yOwKBkcLz4pEJNE4yOSEQvHevcYw> NE\vdmozOzV4NES4Ni=>
SGC7901/LV-NC NVjzSHNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1niSWlEPTB;MT63O-KBkcLz4pEJNE4yPiEQvHevcYw> M4fVflI{PTZ2NEiy
SGC7901/LV-SGO1 MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\M[|lKSzVyPUSuN|bjiIoEsfMAjVAvOzdizsznM41t NVm4cmt2OjN3NkS0PFI>
SGC7901/VCR NFzFPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\5TWM2Oz1{MD61N-KBkcLz4pEJNU46PiEQvHevcYw> NET3NoEzOzV4NES4Ni=>
SGC7901/VCR-NC MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF7Lki25qCKyrIkgJmyMlAyKM7:Zz;tcC=> M4rrflI{PTZ2NEiy
SGC7901/VCR-si-SGO1 MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PtOGlEPTB;Nj6xPQKBkcLz4pEJNU4xOyEQvHevcYw> M{fUXVI{PTZ2NEiy
SGC7901/ADR NWfnT3pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTZTWM2OD15Lki15qCKyrIkgJmwMlY1KM7:Zz;tcC=> Mof5NlM2PjR2OEK=
SGC7901/ADR-NC M3PLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrwNYNJUUN3ME24Mlk{6oDLwsJihKkxNjZ6IN88[{9udA>? MWOyN|U3PDR6Mh?=
SGC7901/ADR-si-SGO1 M2\ISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\tTWM2OD1|LkS25qCKyrIkgJmwMlI6KM7:Zz;tcC=> MoPwNlM2PjR2OEK=
SH-SY5Y  NXy3WItuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTsdWExNjByMT2xNEDPxE1? M1fXblI1KGh? M1O3N2lEPTB;MD6xNVPDuTBwMEGyJO69VQ>? MXOyN|EzQTB4NR?=
SH-SY5Y  NFvrbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\DfWw4OC5yMEGtNVAh|ryP NGG4SW41QCCq M{\jU2lEPTB;MD6wO|jDuTBwMEC5JO69VQ>? NVXmS2RROjNzMkmwOlU>
SH-SY5Y  NG\5PYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmwMlAxOS1zMDFOwG0> MU[3NkBp MWfJR|UxRTBwMEWxxtExNjByODFOwG0> M3jsXVI{OTJ7ME[1
SH-SY5Y NWrLVol4SXCxcITvd4l{KEG|c3H5 M{jp[VAvOSEQvF2= MmLoNE0zPCCq NFXZdZFqdmS3Y3XzJIFxd3C2b4Ppd{Bw\iCVSD3TXVV[KGOnbHzzJIZwdGyxd3nu[{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCC2aHWgS|IwVSCyaHHz[S=> M33sXlI{OTJ7ME[1
SH-SY5Y NWD4OpFkSXCxcITvd4l{KEG|c3H5 NEfPR2UxNjFizszN M4X0dlAuOjRiaB?= MV;pcoR2[2W|IH3peI91cWNiYYLy[ZN1yqB? NGnn[5AzOzF{OUC2OS=>

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
Saline
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03023358 Not yet recruiting Peripheral T Cell Lymphoma Nanfang Hospital of Southern Medical University February 2017 Phase 3
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03003520 Recruiting Lymphoma, Large B-Cell, Diffuse Celgene February 2017 Phase 2
NCT03018626 Not yet recruiting Lymphoma, Large B-Cell, Diffuse Nanfang Hospital of Southern Medical University February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID